TABLE 1

Effects of treatment on clinical characteristics of type 2 diabetic subjects

Troglitazone (n = 10)
Metformin (n = 11)
Pre-RxChange from pre-Rx (%)Pre-RxChange from pre-Rx (%)
Age (years)56 ± 255 ± 2
Weight (kg)110.4 ± 5.44 ± 1*96.3 ± 8.30 ± 1
BMI (kg/m2)36.3 ± 2.24 ± 1*32.2 ± 2.8−0.3 ± 1.0
Fasting glucose (mmol/l)10.7 ± 0.5−36 ± 7*12.2 ± 0.7−31 ± 6*
Fasting insulin (pmol/l)246 ± 42−18 ± 9*222 ± 36−14 ± 6*
Fasting leptin (ng/ml)15.7 ± 7.724 ± 1511.1 ± 3.6−2 ± 6
HbA1c (%)8.6 ± 0.3−19 ± 4*9.2 ± 0.4−17 ± 4*
Glucose disposal rate (mg · kg–1 · min–1)5.21 ± 0.7144 ± 7*6.15 ± 0.4821 ± 9*
  • Data are means ± SE.

  • *

    * P < 0.05 vs baseline for same treatment group;

  • P < 0.05 vs change in metformin treatment group.